Cabenuva superior to daily oral therapy for HIV

ViiV Healthcare's interim analysis of the LATITUDE phase III trial shows Cabenuva, a long-acting injectable antiretroviral treatment, is superior to daily oral therapy in maintaining viral load suppression for individuals with adherence challenges. The Data Safety Monitoring Board recommended stopping randomization and offering eligible participants the long-acting injectable therapy. The study is ongoing in the U.S. and Puerto Rico, with full data to be presented at an upcoming scientific conference.